How to cite item

Progress and challenges of gene therapy for Pompe disease

  
@article{ATM25787,
	author = {Giuseppe Ronzitti and Fanny Collaud and Pascal Laforet and Federico Mingozzi},
	title = {Progress and challenges of gene therapy for Pompe disease},
	journal = {Annals of Translational Medicine},
	volume = {7},
	number = {13},
	year = {2019},
	keywords = {},
	abstract = {Pompe disease (PD) is a monogenic disorder caused by mutations in the acid alpha-glucosidase gene (Gaa). GAA is a lysosomal enzyme essential for the degradation of glycogen. Deficiency of GAA results in a severe, systemic disorder that, in its most severe form, can be fatal. About a decade ago, the prognosis of PD has changed dramatically with the marketing authorization of an enzyme replacement therapy (ERT) based on recombinant GAA. Despite the breakthrough nature of ERT, long-term follow-up of both infantile and late-onset Pompe disease patients (IOPD and LOPD, respectively), revealed several limitations of the approach. In recent years several investigational therapies for PD have entered preclinical and clinical development, with a few next generation ERTs entering late-stage clinical development. Gene therapy holds the potential to change dramatically the way we treat PD, based on the ability to express the Gaa gene long-term, ideally driving enhanced therapeutic efficacy compared to ERT. Several gene therapy approaches to PD have been tested in preclinical animal models, with a handful of early phase clinical trials started or about to start. The complexity of PD and of the endpoints used to measure efficacy of investigational treatments remains a challenge, however the hope is for a future with more therapeutic options for both IOPD and LOPD patients.},
	issn = {2305-5847},	url = {http://atm.amegroups.com/article/view/25787}
}